Literature DB >> 3295743

Gonadotropin-releasing hormone (GnRH) physiology in men and women.

N Santoro, M Filicori, D Spratt, W F Crowley.   

Abstract

The combined approach used in studies of GnRH secretion provided a complimentary array of techniques with which to establish the program of amplitude (dose) and frequency of GnRH secretion in the physiologic state. Normative data in men and women were useful in formulating frequency estimates, which could then be applied to the task of replacement of GnRH in deficient (IHH) individuals. Comparison of the results of therapy with these 'ablation-replacement' models then allowed to arrive closer to the true amplitude or dose of exogenous GnRH required to duplicate the physiologic ideal. In addition to providing insight into the neuroendocrine control of reproduction, these applications provided treatment of various reproductive disorders in men and women. Further expansion of the efforts into other potential defects of endogenous GnRH secretion will ultimately uncover those disorders amenable to therapy.

Entities:  

Keywords:  Amenorrhea; Biology; Clinical Research; Diseases; Economic Factors; Endocrine System; Family Planning; Genital Effects, Female; Genitalia; Genitalia, Female; Gonadotropins; Gonadotropins, Pituitary; Hormones; Luteinizing Hormone; Menstruation Disorders; Physiology; Pituitary Hormone Releasing Hormones--men; Pituitary Hormone Releasing Hormones--women; Reproductive Control Agents; Research And Development; Research Methodology; Technology; Urogenital Effects; Urogenital System

Mesh:

Substances:

Year:  1986        PMID: 3295743

Source DB:  PubMed          Journal:  Acta Med Hung        ISSN: 0236-5286


  1 in total

Review 1.  The role of the prokineticin 2 pathway in human reproduction: evidence from the study of human and murine gene mutations.

Authors:  Cecilia Martin; Ravikumar Balasubramanian; Andrew A Dwyer; Margaret G Au; Yisrael Sidis; Ursula B Kaiser; Stephanie B Seminara; Nelly Pitteloud; Qun-Yong Zhou; William F Crowley
Journal:  Endocr Rev       Date:  2010-10-29       Impact factor: 19.871

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.